Surmodics, Inc. ( SRDX ) NASDAQ Global Select

Cena: 29.02 ( 0.07% )

Aktualizacja 06-23 21:15
NASDAQ Global Select
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 376
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 96%
Ilość akcji: 14 236 000
Debiut giełdowy: 1998-03-04
WWW: https://www.surmodics.com
CEO: Mr. Gary R. Maharaj
Adres: 9924 West 74th Street
Siedziba: 55344-3523 Eden Prairie
ISIN: US8688731004
Opis firmy:

Surmodics, Inc., wraz z spółkami zależnymi, zapewnia technologie modyfikacji powierzchni dla wewnątrznaczyniowych urządzeń medycznych oraz składniki chemiczne do testów immunologicznych i mikromacierzy w diagnostyce in vitro w Stanach Zjednoczonych i na arenie międzynarodowej. Działa w dwóch segmentach, urządzeniu medycznym i diagnostyce in vitro (IVD). Segment urządzeń medycznych angażuje się w dostarczanie technologii powlekania modyfikacji powierzchni w celu zwiększenia dostępu, dostarczania i przewidywalnego wdrażania urządzeń medycznych; oraz technologie powlekania dostarczania leków w celu zapewnienia dostawy leku specyficznego dla miejsca z powierzchni urządzenia medycznego dla wieńcowego, peryferyjnego, neuro-naczyniowego i strukturalnego serca oraz innych rynków, a także projektowania, rozwoju i produkcji interwencyjnych urządzeń medycznych, przede wszystkim balonów i cewników. Segment IVD projektuje, rozwija i produkuje produkty i technologie komponentów do diagnostycznego testu immunologicznego, a także zastosowania testów molekularnych i badań biomedycznych. Ten segment oferuje odczynniki stabilizacji białka, substraty, powłoki powierzchniowe i antygeny. Firma została założona w 1979 roku i ma siedzibę w Eden Prairie w stanie Minnesota.

Wskaźniki finansowe
Kapitalizacja (USD) 414 965 686
Aktywa: 178 562 000
Cena: 29.02
Wskaźnik Altman Z-Score: 6.8
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -20.7
Ilość akcji w obrocie: 96%
Średni wolumen: 81 679
Ilość akcji 14 299 300
Wskaźniki finansowe
Przychody TTM 126 078 000
Zobowiązania: 59 665 000
Przedział 52 tyg.: 26.0 - 42.44
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -1.4
P/E branży: 26.8
Beta: 1.202
Raport okresowy: 2025-07-29
WWW: https://www.surmodics.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Teryl L. W. Sides Senior Vice President & President of Vascular Interventions 744 375 1970
Mr. Timothy J. Arens Senior Vice President of Finance & Information Technology and Chief Financial Officer 645 299 1967
Mr. Charles W. Olson Senior Vice President & President of Medical Device Coatings 618 470 1964
Mr. Gordon S. Weber J.D. Senior Vice President of Legal, General Counsel & Secretary 602 840 1964
Mr. Joseph J. Stich Senior Vice President of Human Resources & President of In Vitro Diagnostics 570 920 1965
Mr. Gary R. Maharaj Chief Executive Officer, President & Director 1 327 263 1963
Mr. John D. Manders Corporate Controller, Vice President of Finance & Principal Accounting Officer 0 1981
Joel Suiter Director of Corporate Development 0 0
Wiadomości dla Surmodics, Inc.
Tytuł Treść Źródło Aktualizacja Link
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance. zacks.com 2025-05-01 17:50:34 Czytaj oryginał (ang.)
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-04-30 15:00:20 Czytaj oryginał (ang.)
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago. zacks.com 2025-04-30 13:20:53 Czytaj oryginał (ang.)
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (. businesswire.com 2025-04-30 11:00:00 Czytaj oryginał (ang.)
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. businesswire.com 2025-04-28 22:00:00 Czytaj oryginał (ang.)
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were. businesswire.com 2025-04-22 11:00:00 Czytaj oryginał (ang.)
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions. zacks.com 2025-04-04 17:40:45 Czytaj oryginał (ang.)
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral arteries. Intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5–10 mm in diameter,. businesswire.com 2025-04-03 11:00:00 Czytaj oryginał (ang.)
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months. zacks.com 2025-03-18 09:50:20 Czytaj oryginał (ang.)
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court. zacks.com 2025-03-07 18:00:26 Czytaj oryginał (ang.)
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR LLC (“GTCR”), which have an equity investment in Biocoat Inc., a maker of medical coatings: “Surmodics. businesswire.com 2025-03-06 23:00:00 Czytaj oryginał (ang.)
FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, with the regulatory agency alleging the deal was anticompetitive. reuters.com 2025-03-06 18:22:33 Czytaj oryginał (ang.)
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2025-02-03 12:35:29 Czytaj oryginał (ang.)
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR. businesswire.com 2025-02-03 09:00:00 Czytaj oryginał (ang.)
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues. zacks.com 2025-01-31 14:20:20 Czytaj oryginał (ang.)
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-01-30 12:35:56 Czytaj oryginał (ang.)
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago. zacks.com 2025-01-30 11:20:14 Czytaj oryginał (ang.)
Here's Why You Should Add Surmodics Stock to Your Portfolio Now SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months. zacks.com 2025-01-23 10:26:09 Czytaj oryginał (ang.)
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX) SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2025-01-14 12:36:15 Czytaj oryginał (ang.)
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock? SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-01-03 15:16:48 Czytaj oryginał (ang.)
Best Momentum Stocks to Buy for January 3rd SRDX and CWAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024. zacks.com 2025-01-03 13:10:23 Czytaj oryginał (ang.)
New Strong Buy Stocks for January 3rd UAA, BRBR, RBA, SRDX and CTRA have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024. zacks.com 2025-01-03 08:26:09 Czytaj oryginał (ang.)
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report? SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-09 08:48:44 Czytaj oryginał (ang.)
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why SurModics (SRDX) could produce exceptional returns because of its solid growth attributes. zacks.com 2024-11-12 15:50:27 Czytaj oryginał (ang.)
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate. zacks.com 2024-11-07 13:10:26 Czytaj oryginał (ang.)
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago. zacks.com 2024-11-06 11:21:13 Czytaj oryginał (ang.)
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce™. businesswire.com 2024-10-30 16:30:00 Czytaj oryginał (ang.)
SRDX Stock Down Despite FDA Clearance for Pounce XL System Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market. zacks.com 2024-10-02 15:35:19 Czytaj oryginał (ang.)
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com 2024-09-06 14:55:40 Czytaj oryginał (ang.)
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2024-09-05 14:35:30 Czytaj oryginał (ang.)
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2024-08-15 14:35:23 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-07-31 15:30:34 Czytaj oryginał (ang.)
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago. zacks.com 2024-07-31 13:21:04 Czytaj oryginał (ang.)
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc . ( Nasdaq : SRDX ), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodics stock they own. globenewswire.com 2024-07-08 18:56:00 Czytaj oryginał (ang.)
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC. prnewswire.com 2024-07-03 19:02:00 Czytaj oryginał (ang.)
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier. zacks.com 2024-06-11 15:41:05 Czytaj oryginał (ang.)
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems. “This is an exciting. businesswire.com 2024-06-10 11:00:00 Czytaj oryginał (ang.)
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report? SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-05-31 16:35:44 Czytaj oryginał (ang.)
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million. zacks.com 2024-05-31 16:31:07 Czytaj oryginał (ang.)